Question explored with the scientific record
Number of claims of myasthenia gravis caused by vaccine injury
The short version: the evidence retrieved does not contain a single study that counts or characterizes vaccine-injury claims of myasthenia gravis.
The evidence you gave me is a collection of papers on the natural history, diagnosis, and treatment of myasthenia gravis (MG) in children and adults [1, 2, 6, 9, 10]. None of them were designed to measure whether vaccination causes MG. None of them report a number of claims, a rate per dose, a comparison of vaccinated to unvaccinated people, or any data from a vaccine-safety surveillance system. The closest any paper comes is a 2016 review of pediatric MG that mentions nothing about vaccines at all [1].
The question asks for a count of vaccine-injury claims for MG. The evidence block you provided does not answer that question. It does not contain a single study that looked for vaccine-associated MG, not in VAERS, not in a claims database, not in a cohort study. The gap is not that the evidence is weak. The gap is that the evidence is absent. No study in this set was funded by a manufacturer or used a surrogate endpoint, because none of them even attempted to address the question.
My call: the evidence retrieved does not contain any data on the number of myasthenia gravis claims attributed to vaccination. Confidence: not clear — the question cannot be answered from this evidence.
Sources examined 17
-
Pediatric Myasthenia Gravis: A Review
A comprehensive review of pediatric myasthenia gravis (juvenile MG), detailing its clinical presentations (especially ocular MG), diagnostic approaches, treatment options, thymic involvement, and outcomes in children, with emphasis on management strategies and prognosis.
DOI: 10.1055/s-0036-1594019 -
The Fetal/Adult Acetylcholine Receptor Antibody Ratio in Mothers with Myasthenia Gravis as a Marker for Transfer of the Disease to the Newborn
This study investigates the stability of the anti-fetal to anti-adult acetylcholine receptor antibody ratio in mothers with myasthenia gravis and its predictive value for neonatal myasthenia gravis in their newborns.
DOI: 10.1212/WNL.48.1.50 -
RAT OR HUMAN ACETYLCHOLINE-RECEPTOR ANTIGEN FOR INVESTIGATION OF MYASTHENIA GRAVIS?
This study investigates the differences in antibody titres to muscle acetylcholine receptors (AChR) in patients with myasthenia gravis (M.G.) using both rat and human AChR as antigens, revealing that human AChR yields higher titres and suggesting a different etiology for congeni…
DOI: 10.1016/s0140-6736(79)90919-x -
The effectiveness of thymectomy on seronegative generalized myasthenia gravis: comparing with seropositive cases
This study investigates the efficacy of thymectomy in patients with seronegative myasthenia gravis (SNMG) compared to those with seropositive myasthenia gravis (SPMG), finding comparable clinical outcomes and remission rates between the two groups.
DOI: 10.1111/j.1600-0404.2006.00733.x -
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
Exploratory analyses of the phase 3 MycarinG trial show that the Myasthenia Gravis Impairment Index (MGII) captures patient-reported and physician-assessed impairment, demonstrating greater MGII change, higher responder and PASS rates with Rozanolixizumab vs placebo, thereby sup…
DOI: 10.1007/s00415-025-13480-8 -
Myasthenia gravis in children: Long‐term follow‐up
This study provides long-term follow-up data on 149 juvenile myasthenia gravis patients, revealing a spontaneous remission rate of 22.4 per 1,000 person-years and highlighting the impact of thymectomy on remission rates based on various clinical characteristics.
DOI: 10.1002/ana.410130506 -
Acetylcholine receptor–specific immunosuppressive therapy of experimental autoimmune myasthenia gravis and myasthenia gravis
This study presents a novel immunosuppressive therapy for experimental autoimmune myasthenia gravis (EAMG) that effectively prevents and suppresses the disease by immunizing rats with bacterially expressed cytoplasmic domains of human muscle nicotinic acetylcholine receptors.
DOI: 10.1111/nyas.13550 -
Myasthenia crisis following percutaneous coronary intervention in a patient with late onset myasthenia gravis: successful treatment of a unique case
This case report describes a 70-year-old female with late onset myasthenia gravis who developed a myasthenia crisis following percutaneous coronary intervention, which was successfully treated with plasmapheresis.
DOI: 10.1007/s12928-012-0154-8 -
Alpha-bungarotoxin blocking antibodies in neonatal myasthenia gravis: frequency and selectivity
This study investigates the presence and frequency of alpha-bungarotoxin blocking antibodies in mothers with myasthenia gravis and their newborns, revealing a correlation between maternal antibody levels and the occurrence of neonatal myasthenia gravis.
DOI: 10.1016/0165-5728(89)90157-4 -
Fetal acetylcholine receptor inactivation syndrome
This study reports on eight infants from four families affected by persistent myopathic features following transient neonatal myasthenia gravis (TNMG) due to maternal myasthenia gravis or elevated acetylcholine receptor antibodies, suggesting that such features may be more commo…
DOI: 10.1212/nxi.0000000000000057 -
A randomized, double‐blind, placebo‐controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
This study demonstrates that eculizumab, a terminal complement inhibitor, significantly improves clinical outcomes in patients with refractory generalized myasthenia gravis, as evidenced by a notable reduction in the quantitative myasthenia gravis score compared to placebo.
DOI: 10.1002/mus.23839 -
Assessment of the status of cell-mediated immunity in cytomegalovirus-infected renal allograft recipients
This study assesses cell-mediated immunity in renal allograft recipients infected with cytomegalovirus (CMV), revealing significant suppression of delayed-type skin reactivity and T-lymphocyte ratios compared to controls, with a notable lack of specific immune response to CMV in…
DOI: 10.1016/0008-8749(78)90171-5 -
Cell-mediated and humoral immune responses in diabetic patients with periodontitis
This study investigates the cell-mediated and humoral immune responses in diabetic patients with periodontitis, revealing significant alterations in immunoglobulin levels compared to nondiabetic controls, while cell-mediated immunity showed no significant differences.
DOI: 10.1016/0030-4220(90)90176-s -
Adjuvanticity of a mutant of heat-labile enterotoxin of E. coli for the induction of measles specific CTL responses after intranasal coimmunization with a synthetic peptide
This study investigates the expression of somatostatin receptors in immune-mediated diseases and evaluates the potential of PLO microparticles as a delivery system for a measles virus CTL epitope, highlighting their immunostimulatory effects.
DOI: 10.1016/s0165-2478(97)86152-4 -
Contact sensitivity to dinitrofluorobenzene and oxazolone in mice: In vitro cell-electrophoretic assay
This study investigates the use of an in vitro cell-electrophoretic assay to assess contact sensitivity in CBA mice sensitized to dinitrofluorobenzene and oxazolone, demonstrating a significant reduction in the electrophoretic mobility of lymph node cells as a reliable indicator…
DOI: 10.1016/0022-1759(82)90085-0 -
RAMP1 in Kupffer cells is a critical regulator in immune-mediated hepatitis
RAMP1 signaling in Kupffer cells suppresses innate and splenic T cell–derived pro-inflammatory cytokines to prevent immune-mediated hepatitis in a ConA-induced mouse model; Ramp1-/- mice show worsened liver injury, splenic macrophage/T cell cytokine production increases, and CGR…
DOI: 10.1371/journal.pone.0200432 -
Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques?
This study investigates the unexpected improvement of complicated atheromatous plaques in patients with advanced non-small-cell lung cancer undergoing nivolumab treatment, suggesting a potential immune-mediated effect on atherosclerosis.
DOI: 10.1093/annonc/mdx718